Scott L Burrows, Chief Financial Officer, on June 25, 2026, sold 15,000 shares in Spyre Therapeutics (SYRE) for $1,307,000. Following the Form 4 filing with the SEC, Burrows has control over a total of 97,994 common shares of the company, with 97,994 shares held directly.
SEC Filing: